硼替咗米联合化疗多发性骨髓瘤疗效观察  

Observation on curative effect of bortezimin combined with chemotherapy for multiple myeloma

作　　者：胡军[1] 高丽霞[1] 吴克雄[1] 张斌[1] 张益枝[1] 傅明伟 王云霞[3] HU Jun;GAO Lixia;WU Kexiong;ZHANG Bing;ZHANG Yizhi;FU Mingwei;WANG Yunxia(Department of Hematology and Oneology,Karamay Central Hospital,Karamay,Xingjiang 834000,China;Blood Diseases Hospital,Chinese Academy of Medical Sciences Tianjin 300041,China;Xinjiang Urumqi Center for Disease Control and Prevention,Urumqi,Xingjiang 830000,China)

机构地区：[1]新疆克拉玛依市中心医院血液肿瘤科,新疆克拉玛依834000 [2]中国医学科学院血液病医院,天津300041 [3]新疆乌鲁木齐市疾病预防控制中心,乌鲁木齐830000

出　　处：《新疆医学》2018年第6期582-585,共4页Xinjiang Medical Journal

基　　金：新疆维吾尔自治区自然科学基金面上项目(2017D01A16)

摘　　要：目的观察硼替佐米联合化疗初治及复发难治多发性骨髓瘤(MM)患者的有效率、安全性。方法回顾性分析2008年1月—2016年12月本院收治的36例硼替佐米初次及复发/难治含硼替佐米再治疗的MM患者。按照欧洲血液与骨髓移植组织制定的标准判断疗效。结果入组患者中男性23例,女性13例,中位年龄60岁;共有34例患者完成了2个周期的化疗,总有效率(ORR)91.8%,完成8个周期并进行疗效评价的30例,ORR均达100%,硼替佐米初次及复发/难治含硼替佐米再治疗MM完全缓解率分别为60.6%VS 33.7%。中位随访12个月,无疾病进展率分别为59%VS 31%。初治及复发组毒副作用主要是血液学毒性(41.3%43.6%)、周围神经病变(31.3%22.8%)、胃肠道反应(13.8%13.0%)、疲乏无力(7.6%12.0%),大多都能耐受。结论硼替佐米联合治疗初治及复发/难治的MM患者ORR及CR率均很高,而且毒副反应可控,治疗疗效可。Objective To observe the efficacy, safety and maintenance treatment after complete remission（CR） of bortezomib combined with chemotherapy in patients with primary treatment and relapsed or refractory multiple myeloma（MM）. Methods A retrospective analysis was made on 36 mm patients with bortezomib who were treated for primary and recurrent/refractory treatment with bortezomib from January 2008 to December 2016 in our hospital. Judging the curative effect according to the standards set by European blood and bone marrow transplantation tissues. Results TThere were 23 males and 13 females in the group, with the median age of 60 years old; A total of 34 patients completed 2 cycles of chemotherapy, with the total effective rate（ORR）of 91.8%; 30 patients completed 8 cycles and evaluated their efficacy, with ORR reaching 100%; the complete remission rate of the two groups was 60.6% vs 33.7%. The median follow-up of 12 months showed that the progression rate of disease-free was 59% vs 31% respectively. The toxic and side effects of groups were mainly hematological toxicity（41.3%,43.6%）, peripheral neuropathy（31.3%,22.8%）, gastrointestinal tract reaction（13.8%,13.0%）, fatigue（7.6% 12.0%）, and most of them could be tolerated. Conclusion Bortezomib combined therapy has high or and Cr rates in mm patients with primary treatment and relapse/refractory, and its toxic and side effects can be controlled, so its therapeutic effect can be achieved.

关 键 词：多发性骨髓瘤 硼替佐米 疗效 安全性 

分 类 号：R733.3[医药卫生—肿瘤]